Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

CD Nomenclature 2015: Human Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology.

Engel P, Boumsell L, Balderas R, Bensussan A, Gattei V, Horejsi V, Jin BQ, Malavasi F, Mortari F, Schwartz-Albiez R, Stockinger H, van Zelm MC, Zola H, Clark G.

J Immunol. 2015 Nov 15;195(10):4555-63. doi: 10.4049/jimmunol.1502033.

2.

Phage display identification of CD100 in human atherosclerotic plaque macrophages and foam cells.

Luque MC, Gutierrez PS, Debbas V, Martins WK, Puech-Leao P, Porto G, Coelho V, Boumsell L, Kalil J, Stolf B.

PLoS One. 2013 Sep 30;8(9):e75772. doi: 10.1371/journal.pone.0075772. eCollection 2013.

3.

Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.

Loisel S, André PA, Golay J, Buchegger F, Kadouche J, Cérutti M, Bologna L, Kosinski M, Viertl D, Delaloye AB, Berthou C, Mach JP, Boumsell L.

Mol Cancer. 2011 Apr 19;10:42. doi: 10.1186/1476-4598-10-42.

4.

CD101 expression and function in normal and rheumatoid arthritis-affected human T cells and monocytes/macrophages.

Jovanovic DV, Boumsell L, Bensussan A, Chevalier X, Mancini A, Di Battista JA.

J Rheumatol. 2011 Mar;38(3):419-28. doi: 10.3899/jrheum.100676. Epub 2010 Dec 15.

PMID:
21159825
5.

Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death.

Golay J, Bologna L, André PA, Buchegger F, Mach JP, Boumsell L, Introna M.

Blood. 2010 Oct 28;116(17):3372-3; author reply 3373-4. doi: 10.1182/blood-2010-06-289736. No abstract available.

6.

IFN-gamma and STAT1 arrest monocyte migration and modulate RAC/CDC42 pathways.

Hu Y, Hu X, Boumsell L, Ivashkiv LB.

J Immunol. 2008 Jun 15;180(12):8057-65.

7.

Semaphorin signaling in the immune system.

Potiron V, Nasarre P, Roche J, Healy C, Boumsell L.

Adv Exp Med Biol. 2007;600:132-44. Review.

PMID:
17607952
8.

Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death.

Friedlein G, El Hage F, Vergnon I, Richon C, Saulnier P, Lécluse Y, Caignard A, Boumsell L, Bismuth G, Chouaib S, Mami-Chouaib F.

J Immunol. 2007 Jun 1;178(11):6821-7.

9.

Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury.

Zhu L, Bergmeier W, Wu J, Jiang H, Stalker TJ, Cieslak M, Fan R, Boumsell L, Kumanogoh A, Kikutani H, Tamagnone L, Wagner DD, Milla ME, Brass LF.

Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1621-6. Epub 2007 Jan 23.

10.

CD molecules 2006--human cell differentiation molecules.

Zola H, Swart B, Banham A, Barry S, Beare A, Bensussan A, Boumsell L, D Buckley C, Bühring HJ, Clark G, Engel P, Fox D, Jin BQ, Macardle PJ, Malavasi F, Mason D, Stockinger H, Yang X.

J Immunol Methods. 2007 Jan 30;319(1-2):1-5. Epub 2006 Dec 4.

PMID:
17174972
11.

The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function.

Rey J, Giustiniani J, Mallet F, Schiavon V, Boumsell L, Bensussan A, Olive D, Costello RT.

Eur J Immunol. 2006 Sep;36(9):2359-66.

12.

The CD160+ CD8high cytotoxic T cell subset correlates with response to HAART in HIV-1+ patients.

Nikolova MH, Muhtarova MN, Taskov HB, Kostov K, Vezenkov L, Mihova A, Boumsell L, Bensussan A.

Cell Immunol. 2005 Oct;237(2):96-105. Epub 2005 Dec 9.

PMID:
16337931
13.

SC3 monoclonal antibody defines a novel specific human B-cell surface antigen differentially expressed on B-cell leukaemias and lymphomas and involved in the proliferation of normal and malignant B lymphocytes.

Nikolova M, Guenova M, Taskov H, Marie-Cardine A, Boumsell L, Bensussan A.

Cell Immunol. 2005 Jul-Aug;236(1-2):92-100. Epub 2005 Sep 27.

PMID:
16197933
14.

CD molecules 2005: human cell differentiation molecules.

Zola H, Swart B, Nicholson I, Aasted B, Bensussan A, Boumsell L, Buckley C, Clark G, Drbal K, Engel P, Hart D, Horejsí V, Isacke C, Macardle P, Malavasi F, Mason D, Olive D, Saalmueller A, Schlossman SF, Schwartz-Albiez R, Simmons P, Tedder TF, Uguccioni M, Warren H.

Blood. 2005 Nov 1;106(9):3123-6. Epub 2005 Jul 14.

15.

Soluble CD100 functions on human monocytes and immature dendritic cells require plexin C1 and plexin B1, respectively.

Chabbert-de Ponnat I, Marie-Cardine A, Pasterkamp RJ, Schiavon V, Tamagnone L, Thomasset N, Bensussan A, Boumsell L.

Int Immunol. 2005 Apr;17(4):439-47. Epub 2005 Mar 3.

PMID:
15746246
16.

CD4+ CD56+ blastic tumor cells express CD101 molecules.

Meyer N, Petrella T, Poszepczynska-Guigne E, Boumsell L, Wechsler J, Bensussan A, Bagot M.

J Invest Dermatol. 2005 Mar;124(3):668-9. No abstract available.

17.

CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival.

Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, Tamagnone L, Boumsell L, Malavasi F.

Blood. 2005 Apr 15;105(8):3042-50. Epub 2004 Dec 21.

18.

Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.

Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, Bagot M, Roujeau JC.

J Allergy Clin Immunol. 2004 Nov;114(5):1209-15.

PMID:
15536433
19.

Evaluation of the potential role of cytokines in toxic epidermal necrolysis.

Nassif A, Moslehi H, Le Gouvello S, Bagot M, Lyonnet L, Michel L, Boumsell L, Bensussan A, Roujeau JC.

J Invest Dermatol. 2004 Nov;123(5):850-5.

20.

CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.

Poszepczynska-Guigné E, Schiavon V, D'Incan M, Echchakir H, Musette P, Ortonne N, Boumsell L, Moretta A, Bensussan A, Bagot M.

J Invest Dermatol. 2004 Mar;122(3):820-3.

21.

Sezary syndrome cells unlike normal circulating T lymphocytes fail to migrate following engagement of NT1 receptor.

Magazin M, Poszepczynska-Guigné E, Bagot M, Boumsell L, Pruvost C, Chalon P, Culouscou JM, Ferrara P, Bensussan A.

J Invest Dermatol. 2004 Jan;122(1):111-8.

22.

Immunopathogenesis of cutaneous T-cell lymphomas.

Bagot M, Boumsell L, Bensussan A.

Hematol Oncol Clin North Am. 2003 Dec;17(6):1313-7, vii. Review.

PMID:
14710886
23.

Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells.

Giraudon P, Vincent P, Vuaillat C, Verlaeten O, Cartier L, Marie-Cardine A, Mutin M, Bensussan A, Belin MF, Boumsell L.

J Immunol. 2004 Jan 15;172(2):1246-55.

24.

Structure and function of the immune semaphorin CD100/SEMA4D.

Elhabazi A, Marie-Cardine A, Chabbert-de Ponnat I, Bensussan A, Boumsell L.

Crit Rev Immunol. 2003;23(1-2):65-81. Review.

PMID:
12906260
25.

Human Leucocyte Differentiation Antigen nomenclature: update on CD nomenclature. Report of IUIS/WHO Subcommittee.

Zola H, Swart B, Boumsell L, Mason DY; IUIS/WHO Subcommittee.

J Immunol Methods. 2003 Apr 1;275(1-2):1-8.

PMID:
12723570
26.

Isolation of a CD8alphaalpha+ CD4- tumour T-cell clone with cytotoxic activity from a CD4+ CD8- cutaneous T-cell lymphoma.

Nikolova M, Echchakir H, Wechsler J, Boumsell L, Bensussan A, Bagot M.

Br J Dermatol. 2003 Jan;148(1):24-9.

PMID:
12534590
27.

Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.

Le Bouteiller P, Barakonyi A, Giustiniani J, Lenfant F, Marie-Cardine A, Aguerre-Girr M, Rabot M, Hilgert I, Mami-Chouaib F, Tabiasco J, Boumsell L, Bensussan A.

Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16963-8. Epub 2002 Dec 16.

28.

Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.

Wechsler J, Bagot M, Nikolova M, Parolini S, Martin-Garcia N, Boumsell L, Moretta A, Bensussan A.

J Pathol. 2003 Jan;199(1):77-83.

PMID:
12474229
29.

Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas.

Nikolova M, Bagot M, Boumsell L, Bensussan A.

Leuk Lymphoma. 2002 Apr;43(4):741-6. Review.

PMID:
12153159
30.

Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.

Nikolova M, Musette P, Bagot M, Boumsell L, Bensussan A.

Blood. 2002 Aug 1;100(3):1019-25.

31.
32.

Controlling the immune system through semaphorins.

Bismuth G, Boumsell L.

Sci STKE. 2002 Apr 16;2002(128):re4. Review.

PMID:
11972358
33.

Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.

Nassif A, Bensussan A, Dorothée G, Mami-Chouaib F, Bachot N, Bagot M, Boumsell L, Roujeau JC.

J Invest Dermatol. 2002 Apr;118(4):728-33.

34.

Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas.

Bagot M, Nikolova M, Schirm-Chabanette F, Wechsler J, Boumsell L, Bensussan A.

Ann N Y Acad Sci. 2001 Sep;941:31-8.

PMID:
11594580
35.

Functional characterization of neurotensin receptors in human cutaneous T cell lymphoma malignant lymphocytes.

Ramez M, Bagot M, Nikolova M, Boumsell L, Vita N, Chalon P, Caput D, Ferrara P, Bensussan A.

J Invest Dermatol. 2001 Sep;117(3):687-93.

36.

Erythrodermic cutaneous T-cell lymphoma with disseminated pustulosis. Production of high levels of interleukin-8 by tumour cells.

Poszepczynska E, Martinvalet D, Bouloc A, Echchakir H, Wechsler J, Bécherel PA, Boumsell L, Bensussan A, Bagot M.

Br J Dermatol. 2001 May;144(5):1073-9.

PMID:
11359402
37.

Increased expression of a novel early activation surface membrane receptor in cutaneous T cell lymphoma cells.

Nikolova M, Tawab A, Marie-Cardine A, Bagot M, Boumsell L, Bensussan A.

J Invest Dermatol. 2001 May;116(5):731-8.

38.

The receptors regulating natural cytotoxic effector functions.

Nikolova M, Boumsell L, Bensussan A.

Arch Immunol Ther Exp (Warsz). 2001;49(2):91-9. Review.

PMID:
11348024
39.

Multiple co-stimulatory signals are required for triggering proliferation of T cells from human secondary lymphoid tissue.

Agrawal SG, Marquet J, Plumas J, Rouard H, Delfau-Larue MH, Gaulard P, Boumsell L, Reyes F, Bensussan A, Farcet JP.

Int Immunol. 2001 Apr;13(4):441-50.

PMID:
11282983
40.

Biological activity of soluble CD100. II. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration.

Delaire S, Billard C, Tordjman R, Chédotal A, Elhabazi A, Bensussan A, Boumsell L.

J Immunol. 2001 Apr 1;166(7):4348-54.

41.
42.

CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor.

Bagot M, Moretta A, Sivori S, Biassoni R, Cantoni C, Bottino C, Boumsell L, Bensussan A.

Blood. 2001 Mar 1;97(5):1388-91.

43.

Functional inhibitory receptors expressed by a cutaneous T cell lymphoma-specific cytolytic clonal T cell population.

Bagot M, Martinvalet D, Echchakir H, Chabanette-Schirm F, Boumsell L, Bensussan A.

J Invest Dermatol. 2000 Dec;115(6):994-9. Erratum in: J Invest Dermatol 2002 Jul;119(1):206. Martinvallet D [corrected to Martinvalet D].

44.

Triggering CD101 molecule on human cutaneous dendritic cells inhibits T cell proliferation via IL-10 production.

Bouloc A, Bagot M, Delaire S, Bensussan A, Boumsell L.

Eur J Immunol. 2000 Nov;30(11):3132-9.

45.

Functional characterization of an IL-7-dependent CD4(+)CD8alphaalpha(+) Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma.

Poszepczynska E, Bagot M, Echchakir H, Martinvalet D, Ramez M, Charue D, Boumsell L, Bensussan A.

Blood. 2000 Aug 1;96(3):1056-63.

46.

Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis.

Echchakir H, Bagot M, Dorothée G, Martinvalet D, Le Gouvello S, Boumsell L, Chouaib S, Bensussan A, Mami-Chouaib F.

J Invest Dermatol. 2000 Jul;115(1):74-80.

47.

CD101 expression by Langerhans cell histiocytosis cells.

Bouloc A, Boulland ML, Geissmann F, Fraitag S, Andry P, Teillac D, Bensussan A, Revuz J, Boumsell L, Wechsler J, Bagot M.

Histopathology. 2000 Mar;36(3):229-32.

PMID:
10692025
48.

Switch in the protein tyrosine phosphatase associated with human CD100 semaphorin at terminal B-cell differentiation stage.

Billard C, Delaire S, Raffoux E, Bensussan A, Boumsell L.

Blood. 2000 Feb 1;95(3):965-72.

49.

Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors.

Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, Roujeau JC.

Clin Exp Immunol. 2000 Jan;119(1):225-30.

50.

[Contribution of immunotherapy to the treatment of T-cell lymphoma of the skin].

Bagot M, Boumsell L, Bensussan A.

Presse Med. 1999 Nov 6;28(34):1911-6. Review. French.

PMID:
10587730

Supplemental Content

Loading ...
Support Center